The cell line is not submitted yet.
(only basic data is shown)
General
iPSC Line |
|
| hPSCreg name | SCTi003-A-4 |
| Cite as: | SCTi003-A-4 |
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 2nd September 2026 |
| Notes | Genome-edited Human iPSC Line, SCTi003-A-4, MYH7 R403Q, referred to as SCTi003-A-4, was generated by CRISPR/Cas9 technology, which introduced the c.1208G>A (p.Arg403Gln) mutation into the endogenous myosin heavy chain 7 (MYH7) locus. The R403Q mutation is a well characterized hypertrophic cardiomyopathy (HCM) mutation associated with altered cross-bridge kinetics and hypercontractility, leading to ventricular hypertrophy, myofibrillar disarray, and clinical HCM pathology (Geisterfer-Lowrance et al.; Witjas-Paalberends et al.).
This product’s parental human induced pluripotent stem cell (hiPSC) line, Healthy Control Human iPSC Line, Female, SCTi003-A (Catalog #200-0511) is a well characterized control line derived from peripheral blood mononuclear cells (PBMCs) of a 48-year-old donor. Targeted gene modifications were confirmed by Sanger sequencing. Post-editing, extensive quality control procedures were undertaken in the manufacturing process for SCTi003-A-4 to ensure optimal product performance and reproducibility. SCTi003-A-4 is karyotypically stable, expresses markers of the undifferentiated state, and remains capable of directed differentiation into all three germ layers including cardiomyocyte lineages relevant for cardiovascular research. This genome-edited hiPSC line and its parental hiPSC line provide a robust, isogenic disease modeling tool for studying biophysical mechanisms of HCM, investigating sarcomeric organization, and evaluating therapeutic interventions targeting cardiac contractility. SCTi003-A-4 is manufactured using mTeSR™ Plus (Catalog #100-0276) and is compatible with STEMdiff™ cell culture media, allowing for standardized high-quality maintenance and differentiation to various cell types including functional cardiomyocytes. Cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols. |
| User feedback | |
Provider |
|
| Generator |
STEMCELL Technologies Inc. (SCT)
Contact:
STEMCELL Technologies Inc. (SCT) |
| Owner | STEMCELL Technologies Inc. (SCT) |
| Distributors | |
External iPSC Databases |
|
| BioSamples | SAMEA123394589 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
Additional restrictions:
For in vitro research use only. Not approved for diagnostic, therapeutic, or clinical applications. Not approved for human or veterinary use in vivo. |
| Subclone of | |
iPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
SCTi003-A.
|
Login to share your feedback, experiences or results with the research community.